REIN登记研究提示透析患者他汀二级预防获益
基于法国REIN登记2010-2023年数据,纳入5534例经历动脉粥样硬化性心血管事件(ASCVD)的透析患者,采用目标试验框架和逆概率加权分析。他汀起始与全因死亡风险降低相关,第4年绝对风险差-6.2%,5年预期寿命增加69天,10年增加135天,且未增加横纹肌溶解或中毒性肝炎住院。
要点
- 透析患者ASCVD事件后起始他汀与全因死亡风险降低相关(RR 0.88)。
- 第4年绝对风险差-6.2%,5年生存获益69天,10年135天。
- 未发现横纹肌溶解或中毒性肝炎住院风险增加。
核心结论
- 透析患者发生ASCVD事件后起始他汀安全,并与十年累积生存获益相关。
研究设计与样本
- 基于法国REIN登记并链接国家医保数据库2010-2023年的观察性研究,采用目标试验框架。
- 纳入5534例经历ASCVD事件的成人透析患者(中位年龄75岁,67%男性)。
- 采用逆概率治疗加权平衡基线特征,估计全因死亡的平均因果效应。
主要发现
- 随访十年内,他汀使用与死亡风险降低相关。
- 生存曲线最大绝对差异在第4年:风险差-6.2%(95%CI:-10.2至-2.2),相对风险0.88(95%CI:0.81至0.96)。
- 5年平均生存获益69天(95%CI:14至125),10年达135天(95%CI:31至239)。
- 两组因横纹肌溶解或中毒性肝炎住院无差异。
临床怎么用
- 对于透析患者发生ASCVD事件后的二级预防,可考虑起始他汀治疗。
- 需结合观察性研究局限性个体化评估获益与风险。
局限性
- 为观察性研究,结论需在观察性局限性内解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: While statins are effective for cardiovascular prevention in the general population, their benefit in patients with CKD G5D (kidney failure treated by dialysis) remains uncertain. Previous randomized controlled trials included mixed populations for primary and secondary prevention while excluding patients with recent cardiovascular events, leaving a knowledge gap regarding statin effectiveness for secondary prevention immediately following an atherosclerotic cardiovascular disease (ASCVD) event. Here, we address this gap by providing real-world evidence. METHODS: We conducted a landmark-based observational study, informed by the target trial framework using the French Renal Epidemiology and Information Network (REIN) registry and merged with data from the French national healthcare system database from 2010 to 2023. We included adults with CKD G5D who experienced an ASCVD event. We used inverse probability of treatment weighting to balance baseline characteristics between statin initiators and non-initiators, thereby estimating the average causal effect on all-cause mortality. Results focus on the relative and absolute risk difference and the life expectancy gain using delta restricted mean survival time (dRMST). RESULTS: The study cohort included 5534 patients (median age: 75 years; 67% male). During the ten years of follow-up, statin use was associated with a reduced risk of mortality. The survival curves reached a maximum absolute difference at year four (risk difference -6.2% (95% CI: -10.2; -2.2); relative risk 0.88 [95% CI: 0.81; 0.96]). Life expectancy extended significantly over time with a mean survival gain of 69 days at five years (95% CI: 14-125) and reaching 135 days at ten years (95% CI: 31-239). No difference was identified between groups regarding hospitalizations for rhabdomyolysis or toxic hepatitis. CONCLUSIONS: In patients receiving dialysis, statin initiation following an ASCVD event is safe and associated with a modest-to-moderate ten-year cumulative survival benefit. While interpreted within observational limitations, this real-world evidence supports their use in this secondary prevention setting.
引用
- Letourneau P, Koppe L, Couchoud C, et al. A study using the REIN registry suggests a statin therapy benefits for secondary prevention in patients receiving dialysis. Kidney Int. 2026. PMID: 42901324. doi:10.1016/j.kint.2026.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。